

BVGH Partnership Hub Snapshot



December 2022 (Final Issue)

Dear WIPO Re:Search Members and Friends,

As I write this letter for the final issue of the Snapshot, I am filled with pride at the achievements of the WIPO Re:Search Consortium—including facilitation of over 185 early-stage R&D collaborations to catalyze innovation for diseases that disproportionately affect the world's poorest communities, and expansion of R&D capacity in LMICs. I celebrate our dedicated Members around the globe who work every day to end the neglect and beat NTDs, malaria, and tuberculosis. I am grateful for all of our partners and friends who have supported the Consortium's efforts and helped us tell our stories to audiences worldwide.

WIPO has developed a [video](#) to commemorate the Consortium's 11 years of successes – I encourage you to watch and share with your networks.

WIPO Re:Search will close on December 31, but the fight continues against infectious diseases that cause immense suffering and death in LMICs. In 2023, BVGH will launch a new health equity-focused program that forges public-private partnerships and builds research capacity to foster global innovation ecosystems. Stay tuned to BVGH's social media channels and website for further details!


As always, please share this Snapshot with your colleagues.

Sincerely,

Jennifer Dent, President & CEO
BIO Ventures for Global Health



WIPO Re:Search Statistics



Click [here](#) for a list of WIPO Re:Search Members.
Click [here](#) for a list of WIPO Re:Search collaborations.

Cornerstones of Collaboration

Sharing Expertise to Advance Antitrypanosomal Drug Discovery



UNIVERSIDAD
DE LA REPÚBLICA
URUGUAY



Sharing of expertise—especially between industry and academia—not only leverages different R&D perspectives, but can be a key component in overcoming drug development challenges. Human African trypanosomiasis (HAT) is a parasitic disease endemic in 36 sub-Saharan African countries, and 65 million people across the continent are at risk of being infected. Dr. Laura Scarone at **Universidad de la República** and Dr. Marcelo Comini at **Institut Pasteur de Montevideo** (both from Uruguay) have identified distamycin analogues with highly potent and selective antitrypanosomal activity in vitro, and a novel mechanism of action. BVGH connected both researchers with experts from **Pfizer Inc.**, who shared non-confidential information on improving the in vivo bioavailability, stability, and delivery of the compounds.

Identifying Novel Malaria Drugs from Zambian Natural Products and Synthetic Compounds



The world saw an estimated 247 million malaria cases and an estimated 619,000 deaths in 2021. The WHO African Region is disproportionately impacted, with 95% of malaria cases and 96% of malaria deaths. To combat increasing resistance to current antimalarial medicines, Dr. Peter Mubanga Cheuka, Lecturer and Researcher of Medicinal Chemistry and Drug Discovery at the **University of Zambia**, is working toward the discovery and development of new malaria drugs derived from Zambian natural products and novel synthetic compounds. With support from **Merck KGaA, Darmstadt, Germany***, Dr. Laurent Dembele at the **University of Bamako (Mali)** will screen selected natural products and synthetic compounds from Dr. Cheuka for antimalarial activity.

*The business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics in the US and Canada.

Special Announcement

Second Abstract Submission Deadline January 18: International Conference on Antiviral Research (ICAR)

[ICAR](#)—the main annual event of the [International Society for Antiviral Research \(ISAR\)](#)—is an interdisciplinary meeting that attracts the interest of chemists, biologists, and clinicians. At ICAR, scientists working throughout the world in basic, applied, and clinical research meet in a collaborative and collegial atmosphere to review recent developments in all areas of antiviral drug discovery and development. ICAR provides a variety of networking opportunities to allow members to reconnect with old friends and colleagues and establish new scientific relationships with leaders in the antiviral field. Both in-person (Lyon, France) and virtual programming options will be available. Invited and confirmed speakers—including Prof. Christian Happi, Director of the [African Centre of Excellence for Genomics of Infectious Diseases \(ACEGID\)](#) at Redeemer's University in Nigeria—are listed [here](#).

[Important Upcoming Deadlines and Dates](#)

Second Abstract Submission Deadline (Posters Only)	January 18, 2023
Early Bird Registration Rate Deadline	February 3, 2023
Late-Breaking Abstract Submission Deadline	February 7, 2023
ICAR (Lyon, France and Virtual)	March 13-17, 2023

BVGH FundFinder Featured Awards

NIH International Centers of Excellence for Malaria Research (U19 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) solicits applications for the International Centers of Excellence for Malaria Research (ICEMR) Program, a multidisciplinary network of Centers that will conduct research in malaria-endemic sites to 1) improve our understanding of malaria pathogenesis, epidemiology, and transmission; and 2) evaluate, optimize, and inform development of interventions to understand, control, eliminate, and eventually eradicate malaria. This program is intended to support research that is conducted primarily in countries in which malaria is endemic, and must provide for significant involvement of local/regional researchers in study design, development, and execution. The letter of intent deadline is April 4, 2023; applications are due May 4, 2023. Learn more and apply [here](#).

Additional Funding Opportunities

- [Nature Awards: Inclusive Health Research Awards](#) – Application Deadline: January 6, 2023.
- [NIH Consortium for Design of TB Drug Regimens \(UM1 Clinical Trial Not Allowed\)](#) – Letter of Intent Deadline: January 8, 2023; Application Deadline: February 7, 2023.
- [NIH NIAID Investigator Initiated Program Project Applications \(P01 Clinical Trial Not Allowed\)](#) – Next Application Deadline: January 11, 2023.
- [Maintaining Immunity after Immunization \(U01 Clinical Trial Not Allowed\)](#) – Application Deadline: January 13, 2023.
- [NIH Research Project Grant \(Parent R01 Clinical Trial Not Allowed\)](#) and [Exploratory/Developmental Research Grant Program \(Parent R21 Clinical Trial Not Allowed\)](#), [Notice of Special Interest](#) for Targeting the Pathogen within the Arthropod Vector – Next Application Deadline: February 5, 2023.

- [NIH Administrative Supplements to Existing NIH Grants and Cooperative Agreements \(Parent Admin Supp Clinical Trial Optional\)](#), [Notice of Special Interest](#) for Administrative Supplements for R25 Data Science Training for Infectious and Immune-mediated Disease Research – Next Application Deadline: February 13, 2023.
- [Stellenbosch Institute for Advanced Study \(STIAS\) Iso Lomso Fellowship](#) – Application Deadline: February 15, 2023.
- [NIH Cooperative Centers on Human Immunology \(U19 Clinical Trial Optional\)](#) – Letter of Intent Deadline: March 8, 2023; Application Deadline: April 7, 2023.
- [DAAD Scholarship Database](#) – Postgraduate scholarships for academic studies in Germany. Look [here](#) for important information for applicants.
- [Boehringer Ingelheim Fonds \(BIF\) Travel Grants](#) – Applications must be submitted at least six weeks, but not more than six months, before anticipated travel.
- [Institute of International Education Scholar Rescue Fund Fellowship](#) – Applications are accepted on a rolling basis; fellowships are awarded quarterly.

For more information about BVGH FundFinder, please email [Cathy Manner](#).



Upcoming Global Health Events

Dates	Event	Location
February 1-2, 2023	Antimicrobial Chemotherapy Virtual Conference	Virtual
March 13-17, 2023	International Conference on Antiviral Research	Lyon, France and Virtual
July 24-25, 2023	International Conference on Emerging Infectious Diseases	London, United Kingdom



*The business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics in the US and Canada.
 **MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA.



Copyright © 2022 BVGH, All rights reserved.

Mailing Address:

2101 Fourth Avenue, Suite 1950, Seattle, WA 98121